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Primary mediastinal large B cell lymphoma (PMBCL)
is an aggressive non-Hodgkin’s lymphoma, predom-
inantly affecting young patients. We analyzed 45 pri-
mary PMBCL tumor biopsies and 3 PMBCL-derived
cell lines for the presence of genetic alterations
involving the major histocompatibility complex
(MHC) class II transactivator CIITA and found
frequent aberrations consisting of structural genomic
rearrangements, missense, nonsense, and frame-
shift mutations (53% of primary tumor biopsies and
all cell lines). We also detected intron 1 mutations in
47% of the cases, and detailed sequence analysis
strongly suggests AID-mediated aberrant somatic
hypermutation as the mutational mechanism.
Furthermore, we demonstrate that genomic lesions
in CIITA result in decreased protein expression and
reduction of MHC class II surface expression,
creating an immune privilege phenotype in PMBCL.
In summary, we establish CIITA alterations as a
common mechanism of immune escape through
reduction of MHC class II expression in PMBCL,
with potential implications for future treatments tar-
geting microenvironment-related biology.INTRODUCTION
Primary mediastinal large B cell lymphoma (PMBCL) is an
aggressive B cell neoplasm, accounting for 2%–4% of non-
Hodgkin’s lymphomas (NHLs). Due to the frequent occurrence
of this disease in the mediastinum of young adults, the putative
cell of origin is thought to be a thymic medullary B cell (Swerdlow
et al., 2008).1418 Cell Reports 13, 1418–1431, November 17, 2015 ª2015 The AuApproximately a decade ago, global gene expression profiling
(GEP) revealed a molecular signature that was able to clearly
differentiate PMBCL from other diffuse large B cell lymphoma
(DLBCL) subgroups. Furthermore, it was shown that PMBCL
and the nodular sclerosis (NS) subtype of classical Hodgkin’s
lymphoma (cHL) exhibit similar gene expression profiles (Rosen-
wald et al., 2003; Savage et al., 2003) and overlapping genomic
imbalances (Joos et al., 2002; Steidl et al., 2011; Wessendorf
et al., 2007). The molecular relatedness of PMBCL and NS-
cHL is also recognized in the current World Health Organization
(WHO) classification in which a new category, gray zone lym-
phoma (GZL), was introduced that is characterized by features
intermediate between cHL (NS subtype) and PMBCL (Swerdlow
et al., 2008). Of note, despite the fact that PMBCL and cHL differ
in their expression of certain B cell lineage markers and tran-
scription factors, the expression of surface major histocompati-
bility complex (MHC) class II molecules seems to be defective in
a considerable fraction of cases—a finding that has been linked
to reduced immunogenicity of the tumor cells and correlates with
inferior survival in both diseases (Diepstra et al., 2007; Roberts
et al., 2006). However, the underlying causes of reduced MHC
class II expression are only partially understood.
Chromosomal rearrangements are prototypic oncogenic
events in various subtypes of B cell NHLs and serve as
disease-defining diagnostic features in clinical practice. Until
recently, evidence for recurrent genomic rearrangements in
PMBCL has been sparse. The evolution of next-generation
sequencing techniques had, and still continues to have, a pro-
found impact on the field of cancer genomics, allowing for
genome- and transcriptome-wide characterization of structural
genomic alterations. By applying these techniques, we previ-
ously identified rearrangements involving CIITA, CD274, and
PDCD1LG2 as common mutational events in PMBCL, cHL and
DLBCL cases arising in immune-privileged sites of the body
(Steidl et al., 2011; Twa et al., 2014, 2015). Importantly, these
structural alterations seem to be critical pathogenic drivers facil-
itating immune escape of the malignant B cell population.thors
However, the full spectrum of genetic changes and related func-
tional phenotypes in lymphomas still remains largely unexplored.
CIITA and its pathogenic relevance were first discovered and
described in a rare but severe immune disorder, named heredi-
tary MHC class II deficiency, or type II bare lymphocyte syn-
drome (BLS) (Steimle et al., 1993). Patients affected by this
heritable disease often harbor loss-of-function mutations within
CIITA, resulting in a lack of MHC class II protein expression.
Because MHC class II expression is mainly restricted to anti-
gen-presenting cells and is indispensable for the display of
foreign antigens to CD4+ T cells, BLS patients often suffer
from multiple infections resulting from an insufficient adaptive
immune response. CIITA expression is regulated by usage of
different promoters in a cell-type-specific manner. Four pro-
moters have been described in the literature (Muhlethaler-Mottet
et al., 1997), and transcripts deriving from these promoters differ
in their first exon. Promoter I is used by dendritic cells, and pro-
moter III (pIII) is restricted to B cells, whereas CIITA expression
from the promoter IV (pIV) can be induced upon interferon g stim-
ulation in a wide variety of different cell types, even without anti-
gen-presenting function. The transcription of theMHC class II lo-
cus is tightly controlled by a multi-protein complex, involving
RFX, X2BP, NF-Y, and CIITA, the latter considered to be the
master transcriptional regulator of MHC class II expression
(Masternak et al., 2000; Scholl et al., 1997).
Here, we describe the full spectrum of genomic alterations of
CIITA in PMBCL, including chromosomal rearrangements, dele-
tions, and coding sequence (CDS) mutations. Detailed analysis
of the affected CIITA sequence segments suggests that CIITA
is a target of aberrant somatic hypermutation, with a critical
role for off-target effects of activation-induced (cytosine) deam-
inase (AID) in the mutational process. Of importance, we demon-
strate that somatic CIITA alterations result in reduced CIITA and
MHCclass II expression in primary tissue samples and that some
of the identified gene mutants are impaired in their ability to
induce MHC class II expression in vitro. Moreover, our data pro-
vide further evidence for somatically acquired immune escape
as an important hallmark in PMBCL and contribute to growing
evidence implicating immune escape as a dominant oncogenic
mechanism across the spectrum of diffuse large B cell lym-
phomas (Challa-Malladi et al., 2011).
RESULTS
PMBCL Cell Lines Display Biallelic Genomic Alterations
of CIITA Resulting in the Reduction of MHC Class II
Expression
We have previously demonstrated that genomic rearrangements
of CIITA occur in various lymphoid malignancies and are highly
recurrent in cHL and PMBCL (Steidl et al., 2011). In order to
inform on the prevalence and different types of genomic aberra-
tions affecting CIITA in PMBCL, we first re-analyzed previously
published whole-transcriptome sequencing (RNA sequencing;
RNA-seq) data of three PMBCL-derived cell lines: Karpas1106P,
MedB-1, and U2940 (Gunawardana et al., 2014). Since we have
reported on a CIITA-PDCD1LG2 fusion in DEV, a nodular-
lymphocyte predominant Hodgkin’s lymphoma (NLPHL)-derived
cell line (Twa et al., 2014; R.S. et al., unpublished data), this wasCell Repalso included in the analysis. In addition, we performed high-res-
olution copy-number (CN) analysis (Affymetrix SNP 6.0 arrays)
and validated the identified single-nucleotide variants (SNVs)
and rearrangements by Sanger sequencing.
No CIITA CN or structural alterations were found in MedB-1,
but we identified two SNVs, one (LRG49: g.23483G > A) resulting
in an amino acid exchange (LRG49: p.71Asp > Asn) in the acidic
domain, and the other (g.35202C > T) altering the amino acid
sequence (p.636Thr > Met) in the conserved NACHT domain
of the CIITA protein. Analysis of individual cDNA clones
showed that these point mutations occur in trans configuration
(Figure 1A).
It has been previously described that the tumor suppressor
SOCS1 is inactivated in the Karpas1106P cell line due to a bial-
lelic deletion in this chromosomal region (Melzner et al., 2006;
Mestre et al., 2005). Interestingly, CIITA is located just 0.5 Mb
telomeric of SOCS1. Analysis of our RNA-seq data revealed a
lack of CIITA mRNA expression in this cell line but detected a
TXNCD11-EMP2 fusion transcript (exon 3 of TXNCD11 spliced
in frame to exon 2 of EMP2; Figure 1B), which is the result of a
genomic deletion encompassing 11 genes, including CIITA,
SOCS1, and CLEC16A, the latter recently shown to be involved
in normal B cell development (Li et al., 2015). The precise
coordinates of the deletion were determined as hg19 chr16:
g.10641751_11825721del.
The SNP array data identified a region in which to perform
a ‘‘PCR walk’’ to inform on the breakpoints of the deletion
encompassing the 50 region of the other CIITA allele, which
were in intron 1 of TVP23A and intron 1 of CIITA (chr16:
g.10899052_10985179del), resulting in the loss of pIII and exon
1 (Figure 1B). Aswould be expected, because TVP23A andCIITA
appear in opposite orientations on the chromosome and the pro-
moter for TVP23A is also deleted, no transcript from this fusion
was detected in the RNA-seq data.
A similar analysis of U2940 led to the discovery of an in-frame
NUBP1-CIITA fusion transcript with the amino terminus of the
predicted chimeric protein encoded by the first nine exons of
NUBP1 and the carboxyl terminus encoded by all but the first
exon of CIITA. The genomic deletion was determined to be
chr16: g.10858971_10974177del (Figure 1C). Detailed informa-
tion on the breakpoint sequence and effect at the transcript level
are highlighted in Figure S1. Since transcription of the NUBP1-
CIITA fusion would be driven by the NUBP1 promoter instead
of the strong B cell CIITA promoter, expression of CIITA from
this allele is expected to be reduced. Indeed, themajority of tran-
scripts detected by RNA-seq (97%) were derived from the sec-
ond allele, which, in this cell line, harbors an SNV (LRG49
g.51104C > T) that results in the loss of the original stop codon
(LRG49 p.1131STOP > R*35; Figure 1C).
By integrating high-resolution CN analysis, FISH (fluorescence
in situ hybridization) mapping, and a stepwise PCR approach,
we were able to decipher the genomic structure of the CIITA re-
arrangements in DEV cells (Figure 1D). One allele is disrupted by
a reciprocal translocation and deletion. The CIITA-PDCD1LG2
fusion has been previously described (Twa et al., 2014), and
similar fusions have been observed in two primary PMBCL tissue
samples (Steidl et al., 2011). The PDCD1LG2-CIITA fusion
(t(9;16)(p24.1;p13.13) (chr9:g.5511575::chr16:g.10971955)) isorts 13, 1418–1431, November 17, 2015 ª2015 The Authors 1419
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Figure 1. Schematic Display of Biallelic CIITA Genetic Alterations Discovered in Three PMBCL Cell Lines and the NLPHL-Derived Cell
Line DEV
(A) MedB-1 is characterized by two missense mutations occurring in trans and leading to amino acid exchanges in functionally relevant protein domains (green,
acidic domain; blue, NACHT domain; red, leucine-rich repeat domain).
(B) Karpas1106P harbors a large deletion encompassingCIITA and SOCS1, leading to a gene fusion between EMP2 and TXNDC11. The other allele is affected by
a genomic deletion, resulting in the disruption of CIITA.
(C) In U2940, a large deletion results in a NUBP1-CIITA fusion transcript. The second allele has acquired a base substitution mutation resulting in the loss of the
stop codon.
(D)CIITA rearrangements in DEV are complex, involving the PD-1 ligandPDCD1LG2 andSOCS1, respectively. See theResults section for detailed description. All
genomic coordinates are given according to the hg19 reference genome.
(E) CIITA mRNA expression levels, as assessed by qRT-PCR and displayed relative to GCBs.
(F) HLA-DR expression, as measured by flow cytometry, is shown for all four cell lines in comparison to an LCL (dashed gray line).
See also Figure S1.linked to a large deletion between CIITA intron 1 and CLEC16A
that includes most of the CDS of CIITA (hg19 chr16:
g.10973066_11275555del). This reciprocal translocation results
in PDCD1LG2 expression driven by the CIITA promoter and a
complex PDCD1LG2-CIITA-CLEC16A rearrangement failing to
encode a functional CIITA protein. Additionally, we identified
an inversion involving the second CIITA allele and SOCS11420 Cell Reports 13, 1418–1431, November 17, 2015 ª2015 The Au(chr16: g.10972393_11348602inv) that would lead to the func-
tional abrogation of CIITA. Again, similar to the findings in Kar-
pas1106P, as a consequence of these biallelic rearrangements,
CIITA mRNA expression was not detectable by qRT-PCR
(Figure 1E).
Given the functional importance of CIITA in the transcriptional
regulation of MHC class II genes, we subsequently analyzedthors
Figure 2. CDS Mutations in Primary PMBCL
Cases
The distribution of CIITA CDS mutations in 44
analyzed primary PMBCL samples identified by
WGS, RNA-seq, TSCA sequencing, and Sanger
sequencing. Variations in non-coding regions,
silent mutations, and known SNPs are not shown.
LRR, leucine-rich repeats.HLA-DR protein expression by flow cytometry (Figure 1F).
Karpas1106P and DEV had no detectable surface HLA-DR
expression, whereas U2940 showed an intermediate expression
level compared to a lymphoblastoid cell line (LCL) used as a con-
trol. Interestingly, the third PMBCL cell line, MedB-1, showed
reduced but remarkably heterogeneous HLA-DR expression.
Of note, an altered CN status of the HLA loci could not be de-
tected in any of these four cell lines.
Comprehensive Analysis of Structural Genomic
Alterations and CIITA CDS Mutations in Primary PMBCL
Cases
Prompted by the observed CIITA aberrations in cell lines, we
next investigated to what extent such genetic alterations could
be detected in primary PMBCL tumors. First, we focused on
the recently published whole-genome sequencing (WGS) and
RNA-seq data of seven cases (Gunawardana et al., 2014). We
identified one case (#19) harboring a somatic CDS mutation
(LRG49: g.35376T > C, p.694Leu > Ser), which has been vali-
dated by deep amplicon sequencing. A second case (#20) re-
vealed a nonsense mutation (g.26496C > T) resulting in the
acquisition of a premature stop codon (p.107Glu > Stop).
Both mutations were independently validated using Sanger
sequencing. Based on these observations, we next screened
for mutations within the 19 coding exons of CIITA and alterations
in the pIII region in a larger cohort of PMBCL biopsies. In total, we
selected 45 cases (‘‘sequencing cohort’’; Table S1) from the
Centre for Lymphoid Cancer (CLC) database at the British
Columbia Cancer Agency (BCCA), based on the availability of
fresh frozen material obtained prior to treatment (Table S1). After
exclusion of known SNPs and silent mutations, we found 16
SNVs within the CDS of 13 clinical samples consisting of 7
nonsense/frameshift mutations, 1 SNV resulting in loss of the
start codon, 4 missense mutations, and 4 splice site alterations
affecting the exon 1 splice donor site. One of these cases (#16)
also harbored a small deletion of 8 bp in the 50 UTR and a partial
deletion of exon 1 that extends into the first intron. In addition, we
observed another case (#2) with four alterations in the pIII region
and a 232-bp deletion that encompasses the entirety of exon 1
from 14 bp upstream of the transcriptional start site extending
into intron 1. One sample (#4) displayed a single base pair
substitution in pIII. Overall, alterations affecting the pIII region
seem to be rare (five mutations in only two cases), whereas
almost half of the CDS mutations (43.8%) occur in the first
exon. The distribution and types of mutations for each exonCell Reports 13, 1418–1431, Noare shown in Figure 2; a detailed assem-
bly of genomic coordinates and the puta-
tive translational impact is given in TableS2. For three PMBCL cases, we confirmed the identified muta-
tions as being of somatic origin by sequencing constitutional
DNA extracted from peripheral blood (Table S2).
To inform on structural chromosomal alterations in our
sequencing cohort, we performed FISH on two tissue microar-
rays (TMAs), encompassing 148 PMBCL cases in total, including
41 of the cases in our sequencing cohort. We also performed
FISH on whole tissue sections from formalin-fixed, paraffin-
embedded (FFPE) tissue biopsies either not represented or not
evaluable on the TMAs. In total, 150 individual specimens were
analyzed, and FISH was evaluable in 116 cases (77%), of which
77 were previously reported (Steidl et al., 2011). Thirty-nine
cases (33.6%) were scored as CIITA break-apart (ba) positive
in the entire cohort (n = 116), including 15 of 41 evaluable sam-
ples (36.6%) in the sequencing cohort. A FISH signal constella-
tion indicative of unbalanced rearrangements and/or deletion
of genomic sequence next to the CIITA breakpoint was found
in 44% of ba-positive cases.
Intron 1 Deletions and Point Mutations Are Highly
Prevalent in Primary PMBCL Cases and Indicative of
AID-Mediated Somatic Hypermutation
We have previously shown that the majority of CIITA transloca-
tion breakpoints in PMBCL cluster within a distinct 1.6-kb-span-
ning region near the 50 end of intron 1 (Steidl et al., 2011;
Figure 3A). Of note, the breakpoints observed in DEV fall in the
exact same region, prompting us to examine in detail the
genomic sequence of this region in our sequencing cohort.
Genomic DNA extending 3 kb from the end of exon 1 into intron
1 was PCR amplified and visualized after agarose gel electro-
phoresis. Deletions were clearly evident in 13 of the 45 primary
PMBCL samples but were not observed in 20 DLBCL cases,
5 reactive lymph nodes, and 3 samples of purified tonsillar
germinal-center B (GCB) cells that were analyzed in comparison
(data not shown), suggesting that these deletions might be a
specific event in PMBCL pathogenesis. Cloning and sequencing
of the aberrant length fragments revealed frequent microdele-
tions; multiple base substitutions; and (more rarely) small inser-
tions, duplications and inversions. As many as 51 alterations
were seen per clone, and multiple SNVs were detected in
some of the alleles lacking visible deletions. In total, 21 cases
from the sequencing cohort were found to have sequence alter-
ations within the first 3 kb of intron 1. The allelic origin of a cloned
sequence can be inferred from the sequence at heterozygous
SNP positions and showed that, at least in some cases, biallelicvember 17, 2015 ª2015 The Authors 1421
Figure 3. CIITA Intron 1 Alterations in Primary PMBCL Samples
Depicted is the genomic locus of CIITA (positions according to LRG49) encompassing the pIII region and the first 3 kb of intron 1.
(A) This panel shows the previously mapped breakpoints (Steidl et al., 2011) as gray triangles and the breakpoints identified in this study (red triangles).
(B) Sequencing analyses revealed multiple genomic aberrations within the first 3 kb of intron 1. Point mutations and deletions detected in individual cases and, if
applicable, in different alleles are shown. In contrast, sequence alterations were rare in reactive GCBs with a mutational load comparable to an epithelial cell line
(A549). Dashed line indicates the TSS.
(C) The pIV region and the alternative exon 1 are frequently affected by deletions and SNVs. These genetic alterations often affect transcription factor binding sites
and responsive elements (shown in boxes). Red triangles indicate deletions, and green dots indicate SNVs.
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sequence variants have been acquired. Emphasizing the
genomic instability of this region in PMBCL, analysis of 15 PCR
clones amplified from purified tonsillar GCB cells of three donors
(five clones per donor) revealed only a total of 9 base substitu-
tions among seven clones. The mutation rate in GCB cells was
similar to the background PCR enzyme-related error rate that
was determined in an epithelial cell line (0.8 variants per clone;
data not shown). A detailed description of the genomic aberra-
tions is given in Figure 3B and Table S3. Interestingly, deletions
and SNVs seemed to be enriched in a region encoding the alter-
native exon 1 of the CIITA transcript that is driven from the
pIV promoter and is inducible in many different cell types upon
interferon g stimulation (Figure 3C). To explore to which extend
CIITA expression can be induced upon interferon g stimula-
tion in PMBCL cell lines, we performed a transcript-specific
qRT-PCR. As expected, Karpas1106P showed no expression
because of the biallelic deletion (see Figure 1). The stimulation
with interferon g resulted in a slight increase of the pIII transcript
(1.4-fold for MedB-1 and 1.3-fold for U2940). Expression of the
pIV transcript increased by 2.3-fold for MedB-1 and 5-fold for
U2940. These data are in agreement with the published literature
confirming a preferential effect of interferon g on pIV in B cells
(Piskurich et al., 2006). No changes in HLA-DR expression
were observed due to the described CIITA alterations in these
cell lines (data not shown).
In some primary tumors, we found clear evidence that a step-
wise accumulation of genetic alterations occurred, indicating
genomic instability and clonal evolution (Figure 4A). Further-
more, the high prevalence of CDS mutations in exon 1 and alter-
ations within the first 3 kb of intron 1 led us to speculate
that these alterations are the result of AID-mediated aberrant so-
matic hypermutation (aSHM). We, therefore, analyzed all SNVs
observed within 2 kb from the translational start site (TSS) to
determine whether they represent transitions or transversions.
In total, 233 transitions and 146 transversions occurred (ratio =
1.6:1), which is considerably skewed compared to the theoreti-
cally expected transition:transversion ratio (1:2). Furthermore,
we found a more significant enrichment in mutated cytosine res-
idues within AID target motifs than one would expect by chance
(c2 test, p < 0.001; Figure 4B). Specifically, cytosine residues
within AGC sequence motifs were most commonly affected (Fig-
ure 4C). We then asked whether AID protein expression is
detectable in the diagnostic biopsy material of PMBCL cases.
Immunohistochemical staining was evaluable in 114 cases.
48.2% (55/114) were considered positive, with a variable per-
centage of tumor cells stained (Figures 4D–4F).
CIITAProtein Expression Is Significantly Correlatedwith
the Presence of GenomicCIITAAberrations andHLA-DR
Expression by IHC
In order to inform on genotype-phenotype correlations, we eval-
uatedCIITA andHLA-DR/DP/DQprotein expression by immuno-
histochemistry (IHC) performed on the aforementioned TMAs.
Only cases with complete information on CIITA FISH-ba status
and on CIITA and HLA-DR/DP/DQ protein expression (n = 103)
were analyzed further. CIITA and HLA-DR/DP/DQ protein
expression (represented as histological scores) showed a signif-
icant correlation (Spearman correlation coefficient, r = 0.232, p =Cell Rep0.018; Figure 5A). Analysis of all available cases with known
CIITA FISH-ba status revealed a significant relationship between
the presence of CIITA rearrangements and decreased CIITA
protein expression (p = 0.01, one-sided Mann-Whitney U test;
Figure 5B). In addition, cases with CIITA ba had lower HLA-
DR/DP/DQ expression, but this did not reach statistical signifi-
cance (p = 0.217, one-sided Mann-Whitney U test; Figure 5C).
The distributions of the percentage of tumor cells positive for
CIITA and HLA-DR/DP/DQ are shown in Figures 5D and 5E,
respectively.
Next, we analyzed in more detail the sequencing cohort of
45 primary tumors for which we had information on CIITA ba sta-
tus, CDSmutations, and intron 1 alterations. By integrating these
data, we were able to show that at least eight cases harbored
biallelic alterations of CIITA. The presence of genomic events
and semiquantitative protein expression levels per case are
summarized in Figure 5F. Representative IHC images of two
PMBCL cases are shown in Figures 5G–5J.
Low expression (histological scores 0–3) of CIITA was signifi-
cantly associated with ba positivity (Fisher’s exact test, two-
tailed p = 0.003), as well as with the presence of ba and CDSmu-
tations combined (p = 0.015).CIITA ba-positive casesweremore
frequently negative for HLA-DR/DP/DQ but, likely due to limited
statistical power, this did not reach significance. No significant
association could be obtained for CIITA or HLA-DR/DP/DQ pro-
tein expression with intron 1 aberrations as well as for moderate/
high AID expression with the presence of any genomic alteration.
To explore the potential impact of reduced MHC class II expres-
sion on the microenvironment and, in particular, T-cell subsets,
we correlated the abundance of CD3-, CD4-, and CD8-positive
subsets with HLA-DR/DP/DQ expression. Importantly, we found
a significant positive correlation for MHC class II expression on
the tumor cell surface with the number of CD4- and CD8-ex-
pressing T cells (Figure S2). However, no significant outcome
correlation was observed for CIITA ba status or for HLA-DR or
AID expression status (data not shown).
HLA-DR Expression Is Restored in the NLPHL Cell Line
DEV by Retroviral Transduction of Wild-Type, but Not
Mutant, CIITA
To study the functional consequences of CIITA mutations, we
generated stably transduced cell lines expressing either wild-
type (WT) or mutant CIITA. The NLPHL-derived cell line DEV
was selected for retroviral transduction experiments because it
completely lacks surface HLA-DR expression due to biallelic
inactivation of CIITA (Figure 1D).
The ectopic reintroduction of the CIITA WT allele into DEV
was able to restore CIITA mRNA and protein expression, as
measured by qRT-PCR and western blot, and resulted in HLA-
DR surface expression levels comparable to LCL levels by flow
cytometry (Figures 6A–6G; see Figure 1D for comparison).
Next, we evaluated the effects of four CIITA missense mutants,
one stop-loss mutant, and the NUBP1-CIITA fusion. The
LRG49 g.51104C > T mutation, resulting in a loss of the original
stop codon (LRG49 p.1131STOP > R*35), showed CIITA mRNA
expression comparable to that of the WT (Figure 6A) but was not
capable of re-establishing HLA-DR expression (Figures 6D,
6E, and 6G). The NUBP1-CIITA fusion only partially restoredorts 13, 1418–1431, November 17, 2015 ª2015 The Authors 1423
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Figure 4. CIITA Is Targeted by AID-Mediated aSHM
(A) Three primary PMBCL samples show clear evidence for subclonal evolution. Additionally acquired genetic aberrations are shown in boxes adjacent to a
particular cloned sequence.
(B) Mutations are significantly enriched at cytosine residues within AID target motifs. Gray bars represent the expected frequency of mutations affecting a
cytosine in an AID-target motif by chance (ratio of cytosine residues within the respective AID target motif to cytosines outside these motifs). Red bars highlight
the observed frequency (***p < 0.001, c2 test).
(C) Absolute frequency of mutated cytosine residues within the genomic context of 2 bp upstream. Red bars indicate AID hotspot targets based on the RGYW/
WRCY motifs.
(D and E) Representative images of a PMBCL case negative (D) and positive (E) for AID. Scale bars, 50 mm, original magnification 3400.
(F) Bars show the distribution of the percentage of AID-positive tumor cells in PMBCL tissue samples as measured by IHC. Colors represent staining intensity.
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Figure 5. Genotype-Phenotype Correlation in Primary PMBCL Tissue Samples
(A) CIITA and HLA-DR/DP/DQ protein expression are significantly correlated in a cohort of 103 evaluable PMBCL cases (Spearman correlation coefficient,
r, = 0.232, p = 0.018). For visualization, jitter has been added to the plot.
(B) Analysis of all available cases with known CIITA FISH-ba status revealed a significant relationship between the presence of CIITA rearrangements and
decreased CIITA protein expression.
(C) The presence of CIITA ba resulted in diminished HLA-DR/DP/DQ expression.
(D) Bars show the distribution of the percentage of CIITA-positive tumor cells in PMBCL tissue samples as measured by IHC. Colors represent staining intensity.
(E) Bars show the distribution of the percentage of HLA-DR/DP/DQ-positive tumor cells in PMBCL tissue samples, asmeasured by IHC. Colors represent staining
intensity.
(F) The table summarizes the genomic data and protein expression of CIITA, HLA-DR/DP/DQ, and AID as quantified using immunohistochemical staining in the
sequencing cohort (n = 45). Asterisks in the first row of the table highlight primary clinical specimenswith confirmed biallelic hits inCIITA. Colored boxes (blue, red,
and green) indicate that the respective genetic alterations are present in this particular sample. 15 tumor biopsies were CIITA ba-positive by FISH; 15 cases
harbored CDSs or pIII mutations; and, in 21 samples, alterations in intron 1 were detected. Samples not assessable for an assay are in gray. Protein expression
level is encoded by color intensity (i.e., low expressers = pale orange, intermediate = medium orange, and high expressers = dark orange).
(G–J) Representative images of case #7, a case harboring a CIITA rearrangement and intron 1 mutations, showing CIITA expression in a small number of tumor
cells (G) and absence of surface HLA-DR expression in this population (H). In contrast, in case #33, no genomic aberrations were detectable, and the majority of
tumor cells showed cytoplasmic and nuclear expression of CIITA (I) and strong surface HLA-DR expression (J).
Scale bars, 50 mm, original magnification 3400. See also Figure S2.
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Figure 6. Ectopic Expression of CIITAWT and Mutants in DEV
(A) No significant differences in CIITA mRNA expression were observed upon retroviral transduction of WT and mutant CIITA (number of independent experi-
ments, n = 3).
(B) CIITA protein expression is restored upon transduction with WT and mutant CIITA. As expected, the p.STOP1131R*35 mutant and the NUBP1-CIITA fusion
protein have a slightly higher molecular weight compared to the WT protein.
(C and D) WT CIITA restores HLA-DR mRNA (C; number of independent experiments, n = 3) and surface protein expression (D; representative data from three
experiments), whereas the p.STOP1131R*35 mutant does not. The missense variants discovered in MedB-1 and two clinical samples have different impact on
HLA-DR expression.
(E) Density plots for GFP and HLA-DR expression in transduced DEV cells.
(F and G) Geometric mean of the fluorescence intensity (FI) for HLA-DR (F; n = 3) and GFP (G; n = 3). Means ± SD are shown for all bar graphs.
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HLA-DR levels and, therefore, explains the intermediate expres-
sion levels seen in U2940 (Figure 1F). Interestingly, the two
different mutant alleles that occur in trans-configuration in
MedB-1 showed approximately equal amounts of CIITA mRNA
and protein (Figures 6A and 6B) but revealed different effects
on HLA-DR expression when independently transduced. Specif-
ically, the p.71Asp > Asnmutation restored HLA-DR surface pro-
tein, whereas the p.636Thr > Met allele displayed a broad range
of expression similar to the parental cell line (Figures 1F, 6D, and
6E). The p.715Cys > Tyr mutant could only marginally restore
HLA-DR expression, whereas with the p.11Ser > Pro allele,
high levels of HLA-DR expression were observed (Figures
6A–6G).
DISCUSSION
Here, we performed a comprehensive analysis of genomic
alterations in CIITA using WGS and transcriptome sequencing
approaches and discovered somatic CDS mutations as well as
deletions and rearrangements in PMBCL cell lines and primary
tumor biopsies. By targeted sequencing, we found that CIITA
mutations were highly recurrent in an extension cohort of
PMBCL; thereby, we substantially expanded on our previous
findings of recurrent CIITA rearrangements in this disease
(Steidl et al., 2011). Overall, CDS mutations together with
structural alterations of the CIITA locus, encompassing dele-
tions and rearrangements, were found in 71% of PMBCL
cases, establishing CIITA as one of the most frequently altered
genes in this lymphoma entity (Steidl and Gascoyne, 2011).
Moreover, our findings in PMBCL-derived cell lines and in a
portion of primary clinical cases establish the pattern of CIITA
biallelic hits.
The pattern of CIITA CDS aberrations, predominantly consist-
ing of nonsense and frameshift mutations, as well as small dele-
tions and chromosomal breakpoints, within a hotspot region in
the first exon and intron is indicative of loss of function. Since
CIITA is known as the master transcriptional regulator of MHC
class II, the impaired function would be expected to lead to a
decrease in MHC class II expression, which has been linked to
reduced tumor cell immunogenicity (Cycon et al., 2009; Rimsza
et al., 2004). By performing functional rescue experiments, we
were able to demonstrate that some of the CIITA missense mu-
tants result in a functionally deficient protein not capable of
inducing HLA-DR surface expression in vitro. Moreover, some
mutations, like the p.636Thr > Met discovered in MedB-1, might
lead to a dominant-negative phenotype, a phenomenon previ-
ously seen by others in functional selection studies (Bontron
et al., 1997; Camacho-Carvajal et al., 2004) and demonstrated
by us for the CIITA-FLJ27352 gene fusion (Steidl et al., 2011).
On the other hand, some altered alleles retained their capability
to activate MHC class II transcription.
In primary PMBCL samples, CIITA and HLA-DR/DP/DQ pro-
tein expression were significantly correlated, underscoring the
role of CIITA as the master transcriptional regulator of MHC
class II. In addition, CIITA CDS mutations and chromosomal re-
arrangements were linked to diminished CIITA and HLA-DR/DP/
DQ protein expression in tumor biopsies. Given the semiquanti-
tative nature of IHC and the low dynamic range of these assays,Cell Repit is difficult to evaluate the exact consequences of a quantitative
reduction in clinical samples with respect to tumor-micro-
environment interaction. However, our correlative studies show
that lower numbers of CD4+ and CD8+ T cells were present in
the microenvironment of tumor biopsies with low MHC class II
expression. These data, together with HLA-DR reduction in
CIITA-mutated PMBCL cell lines, suggest that CIITA mutations
contribute to immune-escape phenomena in this lymphoma
subtype. Since CIITA requires co-factors to induce MHC class
II transcription, it is conceivable that mutations of such co-fac-
tors may further contribute to immune escape. For instance, in
a recently published study, Green et al. (2015) have shown that
CREBBP mutations in follicular lymphoma samples are associ-
ated with lower MHC class II transcript and protein levels.
Further studies are needed to explore the role of CREBBPmuta-
tions in PMBCL and how these might be linked to genomic alter-
ations occurring in CIITA.
Whereas our data demonstrate the functional relevance and
clonal selection of CIITA rearrangements and CDS mutations,
the pathogenic contribution of the clustered intron 1 deletions
and point mutations still needs to be determined. Of note, intron
1 variants were not correlated with either CIITA or MHC class II
expression in our PMBCL sequencing cohort, suggesting that
the majority might be co-selected passenger mutations and
are likely the result of AID-mediated aSHM. However, as many
of these alterations occur within the pIV region and frequently
target transcription factor binding motifs and responsive ele-
ments (Muhlethaler-Mottet et al., 1997), or even entirely delete
this promoter and/or its associated alternative first exon, they
might be of pathogenic relevance. It has been recently shown
in splenic dendritic cells that distal regulatory elements—regions
involved in the regulation of CIITA transcription—are able to
switch to and interact with other downstream promoters if the
pI promoter (from where CIITA is expressed in dendritic cells)
is not accessible (Lohsen et al., 2014). This promoter flexibility
could be a potential ‘‘rescue mechanism’’ for B cells to maintain
high expression levels of CIITA mRNA, despite mutation-associ-
ated loss of pIII-driven transcripts or functional abrogation re-
sulting from mutations in pIII exon 1. Thus, additional functional
abrogation of pIV could be a selective advantage for malignant B
cells.
The clustering of SNVs, deletions and chromosomal break-
points in the first exon and intron as well as a significant associ-
ation with AID target motifs raises the likelihood that in PMBCL
CIITA is aberrantly targeted by the AID-mediated somatic hyper-
mutation process. As it has been shown in previous studies for a
variety of genes (BCL6, MYC, PAX5, PIM1, RHOH, CD95, and
SOCS1) characteristically expressed in germinal-center B cells,
mutations in these loci can occur as a side product of the B cell
maturation and antibody diversification process andmight play a
crucial role in the development of malignant lymphomas of (post)
germinal-center B cell origin (Migliazza et al., 1995; Mottok et al.,
2007, 2009; M€uschen et al., 2000; Pasqualucci et al., 1998,
2001). Following these studies, genome-wide screens and tar-
geted sequencing approaches in mice and humans have identi-
fied a large number of other genes affected by aSHM in both
non-malignant and malignant contexts (Liu et al., 2008; Jiang
et al., 2012; Khodabakhshi et al., 2012; Loeffler et al., 2015;orts 13, 1418–1431, November 17, 2015 ª2015 The Authors 1427
Figure 7. Schematic Figure Highlighting the
Functional Impact of CIITA Alterations in
Malignant Lymphomas
Structural genomic alterations, i.e., rearrange-
ments, result not only in the functional abrogation
of CIITA but also in overexpression of the respec-
tive partner genes such as PD-1 ligands. There-
fore, these alterations might present as ‘‘double-
hits,’’ leading to reduced immunogenicity and the
enforcement of an exhausted T-cell phenotype.
CDS mutations and intron 1 alterations may cause
functional impairment of CIITA, resulting in
reduced levels of MHC class II expression.Okosun et al., 2014). As a result, CIITA is considered to be a
target of aSHM in DLBCL and follicular lymphoma. We show,
in our study, that AID protein expression is detectable in a sub-
stantial fraction of PMBCL tumors. This is in line with previous re-
ports in the literature where the authors observed AIDmRNA and
protein expression but were limited by analyzing only a small
number of tissue biopsies (Bo¨do¨r et al., 2005; Popov et al.,
2007). However, we were not able to demonstrate a significant
association between AID protein expression and the mutational
load in a particular lymphoma sample. This might be explained
by the presence of aSHM earlier in lymphomagenesis (Lei-
tha¨user et al., 2001), a scenario that also likely explains the pres-
ence of aSHM in cHL (Liso et al., 2006), which typically lacks AID
protein expression in the malignant Hodgkin-Reed-Sternberg
cells (Greiner et al., 2005). This observation further emphasizes
the pathophysiological and molecular relatedness of PMBCL
and cHL.
In summary, we have comprehensively analyzedCIITA aberra-
tions in PMBCL, identifying this gene as one of themost frequent
altered genes in this lymphoma subtype. In addition to the
recently reported high expression of programmed death 1 li-
gands (Twa et al., 2014), CIITA and the subsequent MHC class
II abrogation describe an ancillary mechanism that is critically
involved in the establishment of an immune-privilege phenotype
(Figure 7). The identification of acquired immune-privilege
properties harbors the potential to develop and pursue targeted
treatment approaches, such as PD-1 and PD-L blockade
(Armand et al., 2013) or cell-based vaccination (Mortara et al.,
2009), in this molecularly characterized subgroup of B cell
lymphomas.1428 Cell Reports 13, 1418–1431, November 17, 2015 ª2015 The AuthorsEXPERIMENTAL PROCEDURES
Cell Lines and Primary Patient Specimens
The PMBCL-derived cell lines U2940, MedB-1,
and Karpas1106P, as well as the NLPHL-derived
cell line DEV, were previously selected for RNA-
seq (Gunawardana et al., 2014; Twa et al., 2014).
Karpas1106Pwas provided byDr.M. Dyer (Univer-
sity of Leicester) and grown in RPMI 1640 media
(Life Technologies) with 20% heat-inactivated fetal
bovine serum (FBS; Life Technologies). The cell
line U2940 was obtained from Dr. L. Staudt (NIH)
and propagated in RPMI with 10% heat-inacti-
vated FBS. MedB-1 was a kind gift from Drs. S.
Br€uderlein and P. Mo¨ller (Department of Pathol-
ogy, University of Ulm) and propagated as pub-lished previously (Bentz et al., 2001). The cell line DEV was generously
provided by Dr. Arjan Diepstra, University Medical Center Groningen, and
grown in RPMI with 20% heat-inactivated FBS. The LCL was derived from
Epstein-Barr-virus (EBV)-transformed B cells of a healthy male donor and pro-
vided by Dr. Ulrich Steidl, Albert Einstein College ofMedicine. These cells were
grown in RPMI supplemented with 20% FBS, 1% penicillin-streptomycin, 1%
non-essential amino acids, and 1% sodium pyruvate (all from Life Technolo-
gies). In order to validate and expand our findings in cell lines, we identified
and selected diagnostic pretreatment specimens from 45 PMBCL patients
from our database based on the availability of fresh-frozen tissue biopsies or
cell suspensions, which were then retrieved from the tissue archives of the
CLC at the BCCA. Of these 45 samples, 7 PMBCL specimens with available
matched constitutional DNA were previously used for WGS or RNA-seq ana-
lyses (Gunawardana et al., 2014). FFPE tissue specimens were assembled
on tissue microarrays as described previously (Steidl et al., 2011). This study
was approved by the Research Ethics Board of the University of British
Columbia and the BCCA, conducted in accordance with the Declaration of
Helsinki, and informed consent was obtained.
CN Analysis
Affymetrix Human SNP 6.0 microarrays were used to profile the genome-wide
CN status of the cell lines Karpas1106P, U2940, MedB-1, and DEV following
standard protocols according to the manufacturer’s instructions. After quality
control, SNP 6.0 microarrays were pre-processed using the PennCNV-Affy
protocol (Wang et al., 2007). OncoSNP (v1.3; Yau et al., 2010) was then
used to simultaneously segment and predict CN. The CN states of these seg-
ments were subsequently projected onto genes using Ensembl (version 72) as
the scaffold.
Screening for CIITA CDS Mutations and Intron 1 Alterations
Genomic DNA and RNAwere extracted using the AllPrep DNA/RNA Extraction
Kit (QIAGEN). CIITA CDS mutations in primary PMBCL tumor specimens
were detected by re-analysis of the previously generated whole-genome
and/or RNA-seq libraries (n = 7). 30 cases were analyzed by deep amplicon
sequencing (TruSeq Custom Amplicon Assay [TSCA], Illumina; see Sup-
plemental Experimental Procedures for details), and in 18 cases, Sanger
sequencing was performed for all coding exons. One case could not be
completely characterized due to insufficient amounts of nucleic acids; for
details, see Table S1.
All mutation predictions resulting from WGS, RNA-seq, and deep amplicon
sequencing were subjected to validation using Sanger sequencing (3130
Genetic Analyzer, Applied Biosystems, or outsourced to GENEWIZ). Prior to
Sanger sequencing, all CIITA coding exons were amplified by standard
PCR. Deletions in CIITA intron 1 were detected by amplification of a fragment
covering the breakpoint cluster region, and aberrant length fragments (<3 kb)
were cloned into pCR 2.1-TOPO vectors (TOPO TACloning Kit, Invitrogen) and
fully sequenced.
Primer sets are listed in the Supplemental Information (Table S5). Sequence
analysis and assembly was performed using Clone manager software
(Scientific & Educational Software). Genomic coordinates are given according
to the fixed CIITA reference sequence LRG49. For rearrangements involving
genomic loci other than CIITA, the genomic coordinates are given according
to hg19.
IHC
IHC was performed on 4-mm sections from FFPE tissue samples arranged on
previously constructed TMAs (Gunawardana et al., 2014; Steidl et al., 2011) or
on whole tissue sections in the case where a particular sample was not evalu-
able or represented on the TMA. Following antigen retrieval, sections were
stained with the respective antibodies (see Table S4), followed by routine pro-
tocols for automated IHC on the Ventana Benchmark XT (Ventana Medical
Systems). For more details on the evaluation of protein expression, see the
Supplemental Experimental Procedures.
Flow Cytometry and Cell Sorting
Flow cytometry was used to quantify HLA-DR surface expression in cell lines.
Briefly, 0.53 106 cells were washed once in cold PBS containing 1% FBS and
then incubated for 30 min on ice with PerCP/Cy5.5 anti-human HLA-DR
(BioLegend, 0.25 mg per test). PerCP/Cy5.5 Mouse IgG2a k was used as an
isotype control. After washing and resuspension, samples were run on a
FACSCalibur flow cytometer (BD Biosciences). All analyses were done using
FlowJo software (version 10.0.7r2, FlowJo, LLC).
Frozen vials of cells obtained from reactive tonsillar specimens were stained
with purified mouse anti-human CD77 antibody (Clone 5B5, BD Pharmingen)
for 30 min on ice. Cells were then incubated for 15 min at 4C with rat anti-
mouse IgM MicroBeads (Miltenyi) and subsequently separated using auto-
MACS Columns (Miltenyi) in order to enrich for germinal-center B cells.
qRT-PCR
All qRT-PCR assays were performed on a CFX384 real-time PCR system (Bio-
Rad). The efficiencies of target and reference amplifications were verified to be
equal; therefore, expression levels were quantified using the DDCT method. A
TaqMan RNA-to-CT 1-Step Kit and TaqMan gene expression assays were
used to detect mRNA expression levels of CIITA (Hs00932860_m1) and
HLA-DR (Hs00734212_m1). GAPDH expression (GAPDH (DQ) Oligo Mix, cat-
alog no. 4332649, Life Technologies) served as an internal control. Each spec-
imen was assayed in triplicate using 1 ng of total RNA per 10 ml reaction, and
the results are shown relative to the expression in either germinal-center B
cells or cells transduced with the empty vector control.
CIITApIII- andpIV-specificmRNAswere assayedbya two-stepSYBRGreen
assay (Power SYBRGreen PCRMasterMix, Life Technologies). Cell lines were
stimulated with 500 U/ml interferon g (Roche) for 48 hr. cDNA was synthesized
from 1 mg total RNA using random hexamers and SuperScript III Reverse Tran-
scriptase (Life Technologies). cDNA equivalent to 5 ng RNA was used for each
10 ml reaction, and expression levels were normalized to GAPDH.
Western Blotting
Total cell lysates were prepared using RIPA lysis and extraction buffer (Thermo
Scientific). Cultured cell lines were washed once with PBS and then incubated
for 10 min at 37C in RIPA buffer supplemented with a protease inhibitor cock-
tail (Sigma-Aldrich). 25 mg of protein lysates was resolved on a 4%–12%Cell RepNuPAGE Novex Bis-Tris gradient gel (Invitrogen) and transferred to a nitrocel-
lulosemembrane bywet transfer. Blotswere probedwith anti-CIITA antibodies
(clone 7-1H, Abcam, ab49989) at a 1:1,000 dilution. b-actin (A5441; Sigma-
Aldrich) served as an internal loading control (dilution 1:10,000). Horseradish-
peroxidase (HRP)-conjugated anti-mouse IgG (W402B, Promega) was used
to visualize bands using the enhanced chemiluminescence (ECL) system
(Amersham) on a Chemidoc digital imager (Bio-Rad).
Retroviral Transduction
Retroviral transductions were performed as previously described (Ngo et al.,
2006). WT ormutantCIITA cDNAswere amplified using Phusion DNA polymer-
ase (New England Biolabs) and subsequently cloned into the doxycycline-
inducible pRetroCMV/TO/GFP vector. Themutant alleles discovered in clinical
cases were generated from the vector containing the WT allele by using the
QuikChange II XL Site-Directed Mutagenesis Kit according to the manufac-
turer’s instructions (Agilent). The NUBP1-CIITA fusion was cloned using the
Gibson Assembly Master Mix (New England Biolabs). Inserts were verified
using Sanger sequencing (for details, see the Supplemental Experimental
Procedures).
Statistical Analysis
Fisher’s exact test and c2 test were used to analyze contingency tables.
Spearmancorrelation andMann-WhitneyU testwere applied toanalyze the cor-
relation betweendifferent variables. p values< 0.05were considered significant.
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